Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13306852 | 0.88 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL13307130 | 0.87 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL13889594 | 0.85 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDTSHRKDM1A | |
| SCHEMBL13306858 | 0.85 | KDM4E (0.41) | ALDH1A1KDM4EHPGDTSHRKDM1A | |
| SCHEMBL13307128 | 0.85 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL13404405 | 0.83 | ACHE (0.51) | — | |
| SCHEMBL13404414 | 0.82 | ALDH1A1 (0.48) | ALDH1A1DRD2 | |
| SCHEMBL13404418 | 0.81 | ALDH1A1 (0.50) | ALDH1A1DRD2 | |
| SCHEMBL13306994 | 0.80 | KDM4E (0.40) | ALDH1A1DRD2KDM4EHPGDTSHR | |
| SCHEMBL13306857 | 0.79 | ALDH1A1 (0.42) | ALDH1A1DRD2KDM4EHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013202-B1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-16 | — | — | EP | disclosed |
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007122173-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | ALDH1A1 710/4885DRD2 39/4885KDM4E 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.